StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2023, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 23 Feb 2023 16:01:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Thu, 23 Feb 2023 16:01:00 -0500 O.49255766 SBTX SPRY ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Thu, 23 Feb 2023 16:01:00 -0500 O.49255766 SBTX SPRY ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Thu, 23 Feb 2023 16:01:00 -0500 O.49255766 SBTX SPRY ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Thu, 23 Feb 2023 16:01:00 -0500 O.49255766 SBTX SPRY ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Thu, 23 Feb 2023 16:01:00 -0500 O.49255766 SBTX SPRY ARS Pharmaceuticals Announces Presentation of Data Supporting neffy (epinephrine nasal spray) and Real-World Burden of Needle Injectors http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Announces+Presentation+of+Data+Supporting%C2%A0neffy+%28epinephrine+nasal+spray%29+and+Real-World+Burden+of+Needle+Injectors/21269561.html Thu, 23 Feb 2023 16:01:00 -0500 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals Reacquires European Marketing Rights to neffy® (ARS-1) for the Treatment of Type I Allergic Reactions Including Anaphylaxis http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+Reacquires+European+Marketing+Rights+to+neffy%C2%AE+%28ARS-1%29+for+the+Treatment+of+Type+I+Allergic+Reactions+Including+Anaphylaxis/21260671.html Wed, 22 Feb 2023 16:05:00 -0500 A.06822034 A.31066700 O.20026344 O.22422661 O.49255766 SBTX SPRY ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html Thu, 09 Feb 2023 06:30:00 -0500 O.49255766 SBTX SPRY ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html Thu, 09 Feb 2023 06:30:00 -0500 O.49255766 SBTX SPRY ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html Visit StreetInsider.com at http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html for the full story. http://www.streetinsider.com/Press+Releases/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html Thu, 09 Feb 2023 06:30:00 -0500 O.49255766 SBTX SPRY ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html Thu, 09 Feb 2023 06:30:00 -0500 O.49255766 SBTX SPRY ARS Pharmaceuticals to Participate in the SVB Securities Virtual Global Biopharma Conference 2023 http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html Visit StreetInsider.com at http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html for the full story. http://www.streetinsider.com/Globe+Newswire/ARS+Pharmaceuticals+to+Participate+in+the+SVB+Securities+Virtual+Global+Biopharma+Conference+2023/21185870.html Thu, 09 Feb 2023 06:30:00 -0500 O.49255766 SBTX SPRY